Icotrokinra Phase 3 PsO hits 46% complete skin clearance; UC Phase 2b meets endpoint

Protagonist Therapeutics, Inc

Phase 3 ICONIC-LEAD: 46% of icotrokinra patients achieved IGA 0 (completely clear skin) at Week 24; 74% IGA 0/1.
ICONIC-ADVANCE 1&2 met co-primary endpoints and showed superiority over deucravacitinib at Weeks 16 and 24; head-to-head vs ustekinumab (ICONIC-ASCEND) initiated.
Phase 2b ANTHEM-UC: 63.5% clinical response at highest dose at Week 12 vs 27.0% placebo (p<0.001); 30.2% clinical remission vs 11.1% (p<0.001).
Both studies show favorable safety; AEs similar to placebo. Icotrokinra is a first-in-class oral IL-23 receptor antagonist.
Results support potential paradigm shift in plaque psoriasis and ulcerative colitis; partner J&J advancing program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.